Paclitaxel is indicated for the treatment of metastatic breast cancer, metastatic adenocarcinoma of the pancreas and locally ...

Combination treatment could also benefit patients with lung, bowel, pancreatic and other solid cancers who don’t respond to ...

As with all products, we will keep its safety under close review The Medicines and Healthcare products Regulatory Agency ...

Despite its success in advanced melanoma, Bristol Myers Squibb’s fixed-dose PD-1/LAG-3 combo, Opdualag, failed to move the ...

Daiichi Sankyo Company Limited (OTC:DSNKY) and AstraZeneca (NASDAQ:AZN) announced promising results from 3 clinical trials: ...

CHICAGO -- For the first time in a phase III trial, overall survival (OS) in unresectable pancreatic cancer improved ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III IMforte study of Tecentriq® (atezolizumab) in combination with lurbinectedin (Zepzelca®) as a first-line ...

Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma”, "Traws” or "the Company”), a clinical-stage biopharmaceutical company ...

Focus V has shown limited PFS benefit, a high incidence of AEs, and no demonstrated improvement in overall survival.

The ADC market was valued at $8.6bn in 2023, with it forecast to exceed $45bn by 2030, according to analysis by GlobalData.

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate ...